Spots Global Cancer Trial Database for tislelizumab
Every month we try and update this database with for tislelizumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer | NCT05809895 | Triple Negative... | Ociperlimab Tislelizumab Paclitaxel Nab-paclitaxel Carboplatin Placebo Pembrolizumab Gemcitabine | 18 Years - | Novartis | |
| PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer | NCT05880082 | Esophageal Squa... | Tislelizumab | 18 Years - | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | |
| Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer | NCT05809895 | Triple Negative... | Ociperlimab Tislelizumab Paclitaxel Nab-paclitaxel Carboplatin Placebo Pembrolizumab Gemcitabine | 18 Years - | Novartis | |
| A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer | NCT04914390 | Triple-negative... | AT regimen Tislelizumab Anlotinib | 18 Years - 75 Years | Sichuan Provincial People's Hospital | |
| Comparison of Efficacy and Safety of Anti-PD-1 Antibody BGB-A317 Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With NSCLC | NCT03358875 | Non-small Cell ... | Tislelizumab Docetaxel | 18 Years - | BeiGene | |
| A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma | NCT03209973 | Classical Hodgk... | Tislelizumab | 18 Years - | BeiGene | |
| Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC | NCT05516589 | Head and Neck S... | Nab-paclitaxel Cisplatin Tislelizumab Afatinib | 18 Years - | West China Hospital | |
| Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma | NCT04921995 | Recurrent Nasop... Unresectable Na... Chemotherapy Ef... Immunotherapy Stereotactic Bo... | Tislelizumab | 15 Years - 90 Years | Fudan University | |
| Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer | NCT05479240 | Immunotherapy | Tislelizumab Capecitabine oxaliplatin short-range rad... | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma | NCT04730219 | Muscle Invasive... Urothelial Carc... | Tislelizumab Nab paclitaxel | 18 Years - | Tianjin Medical University Second Hospital | |
| Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma | NCT05461235 | PD-1 Antibody DC-Cell NK-Cell Gastrointestina... | Pembrolizumab Nivolumab Sintilimab Toripalimab Camrelizumab Tislelizumab NK-Cell or DC-C... | 18 Years - 70 Years | China Medical University, China | |
| Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer | NCT05044871 | Ovarian Cancer | Pamiparib Bevacizumab Tislelizumab Nab paclitaxel Bevacizumab + N... | 18 Years - | Tongji Hospital | |
| A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab | NCT04261439 | In Escalation: ... In Expansion: M... | NIZ985 Spartalizumab Tislelizumab | 18 Years - | Novartis | |
| Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer | NCT04909775 | Muscle-Invasive... | Tislelizumab Cisplatin Gemcitabine | 18 Years - 75 Years | Ruijin Hospital | |
| Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. | NCT05542342 | Uveal Melanoma | Tislelizumab Sitravatinib Ma... | 18 Years - | Grupo Español Multidisciplinar de Melanoma | |
| BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma | NCT03469557 | Esophageal Squa... | Tislelizumab Cisplatin 5-FU Oxaliplatin Capecitabine | 18 Years - 75 Years | BeiGene | |
| A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma | NCT06010303 | Esophageal Canc... Esophageal Squa... Esophageal Squa... | LBL-007 Tislelizumab Chemotherapy Do... | 18 Years - | BeiGene | |
| Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC | NCT05176925 | Non-small Cell ... | Tislelizumab Sitravatinib | 18 Years - 75 Years | Fudan University | |
| Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma | NCT06253598 | Hepatocellular ... | Recombinant Hum... Lenvatinib Tislelizumab | 18 Years - 75 Years | First Affiliated Hospital Bengbu Medical College | |
| Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma | NCT06331845 | Metastatic Naso... Intermittent Sy... | Gemcitabine Cisplatin Paclitaxel prot... Capecitabine Tislelizumab | 18 Years - 70 Years | Fujian Cancer Hospital | |
| A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | NCT03430843 | Esophageal Squa... | Tislelizumab Paclitaxel Docetaxel Irinotecan | 18 Years - | BeiGene | |
| Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10) | NCT05897268 | Hepatocellular ... | Cryoablation Tislelizumab Lenvatinib | 18 Years - | Fudan University | |
| Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis | NCT06233981 | Hepatocellular ... Radiotherapy Tislelizumab Tumor Thrombosi... | Moderate-dose H... Tislelizumab | 18 Years - 90 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer: From a Multicenter Phase II Cohort to a Phase III Randomized Controlled Study | NCT06312982 | Locally Advance... | Tislelizumab | 18 Years - 75 Years | Beijing Friendship Hospital | |
| Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations | NCT06118658 | Gastric Colorectal Aden... | tislelizumab | 18 Years - 75 Years | China Medical University, China | |
| Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer | NCT05799443 | Colorectal Canc... | Tislelizumab Irinotecan Hydr... cetuximab SBRT | 18 Years - 75 Years | Fujian Cancer Hospital | |
| The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE) | NCT04948034 | Metastatic Colo... | Stereotactic Ab... Fruquintinib Tislelizumab | 18 Years - | Fudan University | |
| Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer | NCT03432598 | Locally Advance... | Tislelizumab Paclitaxel Gemcitabine Etoposide Pemetrexed Cisplatin Carboplatin | 18 Years - 75 Years | BeiGene | |
| Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab | NCT05319639 | Gastric Cancer ... | Oxaliplatin Levo-Leucovorin 5-fluorouracil Paclitaxel Irinotecan Tislelizumab | 18 Years - 75 Years | Fujian Cancer Hospital | |
| A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC | NCT05228496 | Lung Cancer, Sm... | Tislelizumab Sitravatinib | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC | NCT03412773 | Hepatocellular ... | Tislelizumab Sorafenib | 18 Years - | BeiGene | |
| Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study | NCT04913571 | Triple Negative... | Eribulin Tislelizumab | 18 Years - 70 Years | Fudan University | |
| A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases | NCT06218888 | Colo-rectal Can... | Tislelizumab Fruquintinib Chidamide | 18 Years - 75 Years | Fujian Cancer Hospital | |
| A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors | NCT05981703 | Advanced Solid ... Solid Tumor | BGB-26808 Tislelizumab | 18 Years - | BeiGene | |
| Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC | NCT04952753 | Metastatic Colo... | NIS793 Bevacizumab Modified FOLFOX... FOLFIRI Tislelizumab | 18 Years - | Novartis | |
| Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma | NCT05024266 | Lung Squamous C... Neoadjuvant The... Immunotherapy | Tislelizumab | 18 Years - 75 Years | First Affiliated Hospital of Zhejiang University | |
| Tislelizumab as Cross-line Treatment for Advanced NSCLC | NCT05192681 | Advanced Non-sm... | Tislelizumab | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma | NCT05687357 | Gastric Cancer Gastroesophagea... | Tislelizumab S-1 Oxaliplatin Nab paclitaxel Radiation | 18 Years - 75 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC | NCT04973306 | Esophageal Squa... Esophageal Squa... | Neoadjuvant Che... Tislelizumab Ivor-Lewis or M... | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| IN10018 Combination Therapy in Treatment-naïve ES-SCLC | NCT06030258 | Small Cell Lung... | IN10018 Tislelizumab Carboplatin Etoposide | 18 Years - 75 Years | InxMed (Shanghai) Co., Ltd. | |
| Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer | NCT05900921 | Advanced Squamo... | Trilaciclib Carboplatin Paclitaxel Tislelizumab | 18 Years - 75 Years | Sichuan University | |
| Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary | NCT05241132 | Cancer of Unkno... Bone Cancer Met... Tislelizumab Gene Mutation-R... Immune Evasion,... Chemotherapy Ef... | Tislelizumab pl... | 18 Years - | Shanghai Changzheng Hospital | |
| Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies | NCT02795182 | Lymphoma Leukemia | Zanubrutinib Tislelizumab | 18 Years - | BeiGene | |
| Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer | NCT05160727 | Mismatch Repair... Colorectal Canc... Microsatellite ... | Tislelizumab Irinotecan radiotherapy | 18 Years - 70 Years | Zhejiang Cancer Hospital | |
| A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC | NCT05877820 | Fumarate Hydrat... | Tislelizumab Lenvatinib | 18 Years - 80 Years | RenJi Hospital | |
| Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma | NCT04652492 | Hepatocellular ... | Tislelizumab in... | 18 Years - 70 Years | Zhongda Hospital | |
| A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL Study | NCT04814069 | Head and Neck C... Radiation PD-1 | Tislelizumab | 18 Years - 70 Years | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma | NCT05984342 | Esophageal Squa... | Tislelizumab | 18 Years - 70 Years | Affiliated Cancer Hospital of Shantou University Medical College | |
| Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma | NCT04486391 | Classical Hodgk... | Tislelizumab Salvage Chemoth... | 18 Years - | BeiGene | |
| Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC | NCT05176925 | Non-small Cell ... | Tislelizumab Sitravatinib | 18 Years - 75 Years | Fudan University | |
| Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer | NCT05634564 | Pancreatic Carc... | Tislelizumab Gemcitabine Nab paclitaxel Hypofractionate... | 18 Years - | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System. | NCT05036798 | Potentially Res... | Tislelizumab | 20 Years - 79 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma | NCT05104801 | Melanoma | sitravatinib tislelizumab | 18 Years - | Peking University Cancer Hospital & Institute | |
| Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma | NCT05909904 | Head and Neck S... Head and Neck C... | Tislelizumab BGB-A425 LBL-007 | 18 Years - | BeiGene | |
| A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC | NCT05896059 | Extensive Stage... | Tislelizumab Anlotinib | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma | NCT04401800 | Hepatocellular ... Unresectable He... Metastatic Hepa... | Lenvatinib Tislelizumab | 18 Years - 70 Years | BeiGene | |
| First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer | NCT05189457 | Prostate Cancer Stage IV Prosta... | Luteinizing Hor... New Hormonal Ag... Docetaxel Tislelizumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma | NCT05668884 | Biliary Tract C... | Combination of ... | 18 Years - 75 Years | Fudan University | |
| Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma | NCT06056336 | Esophageal Squa... Neoadjuvant Che... Adjuvant Therap... | Tislelizumab | 18 Years - 75 Years | Shanghai Chest Hospital | |
| Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma | NCT04672330 | Neoadjuvant Imm... | Tislelizumab | 18 Years - 75 Years | RenJi Hospital | |
| A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT | NCT04843267 | Hodgkin Lymphom... Chemotherapy Ef... | Tislelizumab | 18 Years - 80 Years | Sun Yat-sen University | |
| Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma | NCT05461235 | PD-1 Antibody DC-Cell NK-Cell Gastrointestina... | Pembrolizumab Nivolumab Sintilimab Toripalimab Camrelizumab Tislelizumab NK-Cell or DC-C... | 18 Years - 70 Years | China Medical University, China | |
| Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma | NCT04837859 | Classical Hodgk... | Tislelizumab | 18 Years - | University of Cologne | |
| TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer | NCT05314101 | Immunotherapy Colorectal Canc... | Tislelizumab bevacizumab TAS-102 | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer | NCT04906044 | Tislelizumab Locally Advance... Total Neoadjuva... PD-1 | Sintilimab | 18 Years - 80 Years | The First Hospital of Jilin University | |
| Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002) | NCT05520619 | Esophageal Squa... Locally Advance... | Paclitaxel, Cis... tislelizumab Radiotherapy | 18 Years - 70 Years | Sun Yat-sen University | |
| PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC | NCT06375109 | Limited-stage S... | Tislelizumab Carboplatin inj... Cisplatin injec... Etoposide injec... | 18 Years - 75 Years | Beijing Chest Hospital, Capital Medical University | |
| A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC | NCT05519865 | Non Small Cell ... | Tucidinostat Tislelizumab | 18 Years - | Chipscreen Biosciences, Ltd. | |
| Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy | NCT04541277 | Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... | Tislelizumab | 18 Years - | Chinese PLA General Hospital | |
| Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma | NCT05909904 | Head and Neck S... Head and Neck C... | Tislelizumab BGB-A425 LBL-007 | 18 Years - | BeiGene | |
| Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer | NCT05303090 | Pancreatic Duct... | H101 Tislelizumab lenvatinib | 18 Years - | Fudan University | |
| Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma | NCT05909904 | Head and Neck S... Head and Neck C... | Tislelizumab BGB-A425 LBL-007 | 18 Years - | BeiGene | |
| A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC | NCT05228496 | Lung Cancer, Sm... | Tislelizumab Sitravatinib | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| ALPPS Combined With Tislelizumab in Liver Malignancy | NCT04996446 | Liver Malignant... | Tislelizumab ALPPS surgery | 18 Years - 70 Years | Fudan University | |
| A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy | NCT06356675 | Advanced NSCLC | Tislelizumab Anlotinib | 18 Years - 75 Years | The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine | |
| A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | NCT04577963 | Triple Negative... Endometrial Can... Solid Tumor, Un... Colorectal Canc... | Fruquintinib Tislelizumab | 18 Years - | Hutchmed | |
| A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma | NCT06010303 | Esophageal Canc... Esophageal Squa... Esophageal Squa... | LBL-007 Tislelizumab Chemotherapy Do... | 18 Years - | BeiGene | |
| HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma | NCT06333561 | Hepatocellular ... Lenvatinib PD-1 Inhibitor Hepatic Arteria... | Hepatic arteria... Lenvatinib Tislelizumab Toripalimab Sintilimab Camrelizumab | 18 Years - 75 Years | Sun Yat-sen University | |
| Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy | NCT05614453 | Metastatic Cerv... | Tislelizumab Sitravatinib | 18 Years - | Australia New Zealand Gynaecological Oncology Group | |
| A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | NCT05238883 | Gastric Cancer Renal Cell Carc... Melanoma Sarcoma Testicular Germ... Cervical Cancer Mesothelioma Non Small Cell ... Head and Neck S... | HFB200301 Tislelizumab | 18 Years - | HiFiBiO Therapeutics |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
